CAR T-Cell Therapies Drive Outcomes in Lymphoma, Myeloma – PR Newswire (press release)
Medical Xpress |
CAR T-Cell Therapies Drive Outcomes in Lymphoma, Myeloma
PR Newswire (press release) ATLANTA, Dec. 10, 2017 /PRNewswire-USNewswire/ — For people with certain types of aggressive, refractory blood cancers, treatment options are woefully limited. But three studies being presented today at the 59th American Society of Hematology (ASH … Landmark CAR–T cancer study published Phase 2 CAR–T study reports significant remission rates at 15-month follow up New Data for FDA-Approved CAR T Therapy Show Significant Remission Rates in 42% of Non-Hodgkin Lymphoma … |
